Advanced Airborne Particle Detection in Automated Visual Inspection

When particulate contamination in parenteral products is discussed, attention typically turns to glass fragments, rubber stopper abrasion, or fibers shed from packaging materials. One contamination pathway is frequently underappreciated, even though it is well established in regulatory guidance: the surrounding air itself.

Why is identifying Airborne Particles a challenge?

Cleanrooms are not particle free environments but particle-controlled environments. ISO 14644 1:2015 defines a cleanroom as a room in which the number concentration of airborne particles is controlled and classified, designed and operated to limit how particles are introduced, generated, and retained [1]. 

FDA guidance on visual inspection of injectable products draws a consistent distinction [3]: Intrinsic particles originate from the product itself or from product-contacting components (glass, stoppers, filters, piping), while extrinsic particles originate from the process environment, where product contact was never intended. Airborne particles usually fall into this second category, and their presence in a released product is interpreted by regulators as a signal of deficiencies in environmental control, equipment design, or maintenance [2]. They are also considered a higher microbiological risk, since airborne particles are frequently associated with airborne microorganisms rather than occurring as free-floating entities [1].

This is why a documented, product-specific particle source risk assessment, covering every plausible source for a given process, is expected as part of a Contamination Control Strategy under the revised Annex 1 [4,5]. 

A risk assessment is the prerequisite for configuring an inspection system that can respond to it. An automated visual inspection system does not know what it is looking for; it must be intentionally configured. Automated visual inspection operates along a statistical probability curve governed by particle size, morphology, and container configuration [6]. By increasing optical sensitivity, smaller particles are detected, but pushing past an optimal threshold triggers a sharp spike in false rejects, discarding pristine, non-contaminated. Every AVI system operates somewhere along this curve; the critical differentiator is whether its placement was calculated or arbitrary.

This is where the particle source risk assessment becomes essential. It establishes a baseline of realistic threats for a specific product, container, and process, outlining both particle type and probability of occurrence. Glass, stopper fragments, fibers, and airborne environmental particles do not manifest with equal frequency or optical characteristics. Without this data, an inspection system is calibrated against theoretical assumptions rather than operational reality, either letting critical defects slip through or penalizing yield over harmless visual artifacts. To be effective, this risk assessment must precede inspection recipe creation. It dictates where to weigh optical sensitivity, identifies which container positions demand attention, and defines what a rigorous validation protocol must encompass [7,8].

 

Differentiating External Artifacts from Internal Defects to Protect Process Yield

Environmental control determines whether an airborne particle enters a container during filling. Once a vial or syringe is sealed, responsibility shifts entirely to inspection. That is the mandatory 100% visual inspection USP <790> requires, meant to show that a parenteral product is essentially free from visible particulates [9,10]. This is precisely where specialized optical engineering becomes critical and where WILCO's core expertise comes in.

 

The False Reject Challenge: External Dust vs. Internal Defects

The detection challenge is inherently probabilistic, not binary. Human visual detection performance does not follow a sharp accept or reject threshold; it follows a probability curve that depends on particle size, morphology, and container configuration [11, 12]. Any inspection system, human or automated, must therefore be validated against this established benchmark, demonstrating detection capability at least equivalent to qualified human inspection across the realistic range of particle types a given process can produce [2,11]. 

However, airborne particles introduce a dual challenge: they do not merely risk missed detections inside the container; they can represent a major driver of false rejects on the outside. A particle that simply settles on the exterior surface of a vial—never contacting the fill volume—can easily be flagged by conventional cameras as an internal contaminant. Upping sensitivity increases this issue, penalizing yield over non-defect surface dust. Although turning sensitivity up catches smaller particles, it also starts rejecting containers that were never contaminated in the first place, something observed even during machine qualification on genuinely clean vials [13]. 

 

Automated Inside/Outside Discrimination: The Key to Yield Protection

This is where standardized, one size fits all inspection setups reach their limits and where customized inspection configuration earns its value. Particle visibility thresholds shift with container configuration and fill volume [12]. Sensitivity to optical artifacts shifts with inspection geometry, illumination, and camera position [14].

Instead of running generic configurations, WILCO builds the optical setup, sensitivity, and inspection sequence around the specific product, container, and defect profile. By deploying custom camera geometries, targeted illumination, and particle tracking, the system can differentiate between:

• External surface particles: dust, fibers, or environmental debris sitting harmlessly on the outer glass surface.
• Internal contaminants: True extrinsic or intrinsic particulates 

By dynamically isolating exterior surface artifacts from true internal contamination, an automated setup catches genuine airborne risks inside the product while directly suppressing the false reject rate (FRR).

Validation, in turn, depends on knowing what to validate against. A validation exercise only proves equivalence to the human benchmark if it actually covers the intrinsic and extrinsic particle types a process is likely to produce, and that starts with a proper particle source risk assessment [4,5]. Airborne particles, precisely because they originate outside the product contact path, are easy to omit from this exercise, if the assessment is not deliberately extended to cover the process environment. Inspection systems validated without this input risk being tuned to the wrong particle population, either missing genuine extrinsic contamination or rejecting too aggressively for artifacts that were never a real risk to begin with. 

 

Conclusion 

Airborne particles illustrate why visual inspection cannot be considered in isolation from the upstream manufacturing environment or from the specific optical and mechanical configuration of the inspection system itself. Environmental control and risk assessment determine what particles a process can realistically generate; inspection technology determines whether those particles are reliably caught without excessive false rejection. 

Closing this loop requires an inspection architecture built to differentiate true internal contamination from external surface artifacts. By aligning custom optical configurations with your facility’s specific particle risk profile, you eliminate false rejects and secure uncompromising compliance.

References 

[1] General Chapters: <1116> Microbiological Evaluation of Clean Rooms and Other Controlled Environments. USP-NF. http://ftp.uspbpep.com/v29240/usp29nf24s0_c1116.html 

[2] Inspection of Injectable Products for Visible Particulates. U.S. Food and Drug Administration, guidance for industry. https://www.fda.gov/media/154868/download 

[3] General Chapter <787> Subvisible Particulate Matter in Therapeutic Protein Injections. USP-NF. https://doi.usp.org/USPNF/USPNF_M6497_02_01.html 

[4] CCS Contamination Control Strategy Annex 1 Practices: Case Study. A3P, 2022. https://www.a3p.org/en/contamination-control-strategy-practices-a-case-study-of-a-ccs-implementation/ 

[5] Visual Inspection of Injectable Products: Why the Visible Particulate Matter Test Is Required. Eyetec Blog, 2025. https://www.eyetec.be/blog/post/visual-inspection-of-injectable-products/ 

[6] Definition of Particle Visibility Threshold in Parenteral Drug Products, Towards Standardization of Visual Inspection Operator Qualification. PubMed, 2025 (PMID: 39730203). Available at: https://pubmed.ncbi.nlm.nih.gov/39730203/ 

[7] CCS Contamination Control Strategy Annex 1 Practices: Case Study. A3P, 2022. Available at: https://www.a3p.org/en/contamination-control-strategy-practices-a-case-study-of-a-ccs-implementation/ 

[8] Visual Inspection of Injectable Products: Why the Visible Particulate Matter Test Is Required. Eyetec Blog, 2025. Available at: https://www.eyetec.be/blog/post/visual-inspection-of-injectable-products/ 

[9] General Chapter <790> Visible Particulates in Injections. USP-NF. https://doi.usp.org/USPNF/USPNF_M7197_01_01.html 

[10] Industry Perspective on Medical Risk of Visible Particles in Injectable Products. Parenteral Drug Association (PDA). https://www.pda.org/docs/default-source/website-document-library/publications/industry-perspective-on-medical-risk-of-visible-particles-in-injectable-products.pdf 

[11] Shabushnig JG. Visual Inspection of Injectable Products. FDA presentation, 2022. https://www.fda.gov/media/162175/download 

[12] Definition of Particle Visibility Threshold in Parenteral Drug Products, Towards Standardization of Visual Inspection Operator Qualification. PubMed, 2025 (PMID: 39730203). https://pubmed.ncbi.nlm.nih.gov/39730203/ 

[13] Challenges and Strategies for Implementing Automated Visual Inspection for Biopharmaceuticals. Pharmaceutical Technology. https://www.pharmtech.com/view/challenges-and-strategies-implementing-automated-visual-inspection-biopharmaceuticals 

[14] Automated Visual Particle Inspection. Pharmaceutical Technology, 2026. https://www.pharmtech.com/view/automated-visual-particle-inspection